Copyright
©The Author(s) 2021.
World J Gastroenterol. Sep 28, 2021; 27(36): 6142-6153
Published online Sep 28, 2021. doi: 10.3748/wjg.v27.i36.6142
Published online Sep 28, 2021. doi: 10.3748/wjg.v27.i36.6142
Table 1 Baseline characteristics of the inflammatory bowel disease group and the control group
Parameter | IBD group (n = 50) | Control group (n = 50) | P value1 |
Male gender, n (%) | 31 (62) | 29 (58) | 0.838 |
Age (yr) | 44.3 ± 14.8 | 40.6 ± 12.3 | 0.181 |
Body weight (kg) | 78.4 ± 14.0 | 81.1 ± 15.0 | 0.356 |
Body height (cm) | 176.9 ± 9.8 | 179.6 ± 7.9 | 0.130 |
Body mass index (kg/m2) | 23.9 ± 3.7 | 24.9 ± 3.4 | 0.136 |
SBP (mmHg) | 119.5 ± 11.2 | 116.6 ± 9.2 | 0.156 |
DBP (mmHg) | 77.7 ± 8.3 | 75.0 ± 8.6 | 0.112 |
Smoking, n (%) | 12 (24.0) | 9 (18.4) | 0.660 |
Disease duration (yr)2 | 6.0 (3.0-11.0) | - | - |
UCEIS (score) | 6.0 (5.0-7.0) | - | - |
SES-CD (score) | 9.2 (6.6-12.0) | - | - |
Aminosalycilates | 32 (64.0%) | - | - |
DMARD | 15 (30.0%) | - | - |
Monoclonal antibodies | 29 (58.0%) | - | - |
Table 2 Laboratory parameters of the inflammatory bowel disease group and the control group
Parameter | IBD group (n = 50) | Control group (n = 50) | P value1 |
Erythrocytes (× 1012/L) | 4.7 ± 0.5 | 5.0 ± 0.4 | 0.020 |
Hemoglobin (g/L) | 140.4 ± 17.3 | 148.1 ± 13.7 | 0.015 |
Fasting glucose (mmol/L) | 5.1 ± 0.9 | 5.0 ± 0.6 | 0.653 |
Urea (mmol/L) | 4.7 ± 1.5 | 5.6 ± 1.6 | 0.004 |
Creatinine (μmol/L) | 71.4 ± 15.3 | 75.9 ± 14.7 | 0.134 |
Total proteins (g/L) | 71.2 ± 6.6 | 72.1 ± 3.9 | 0.394 |
Albumins (g/L) | 39.5 ± 5.1 | 43.7 ± 2.4 | < 0.001 |
hsCRP (mg/L) | 3.4 ± 2.6 | 1.2 ± 1.1 | < 0.001 |
Triglycerides (mmol/L) | 1.3 ± 0.9 | 1.1 ± 0.6 | 0.311 |
Total cholesterol (mmol/L) | 4.8 ± 1.3 | 5.2 ± 1.2 | 0.091 |
HDL cholesterol (mmol/L) | 1.3 ± 0.4 | 1.4 ± 0.3 | 0.447 |
LDL cholesterol (mmol/L) | 2.6 (2.1-3.4) | 3.2 (2.4-3.9) | 0.018 |
FC (μg/g) | 231 (61.5-619.2) | - | - |
Table 3 Correlation analysis between serum urotensin II levels and different biochemical, anthropometric and clinical parameters in the inflammatory bowel disease group (n = 50)
Parameter | r1 | P value |
hsCRP (mg/L) | 0.491 | < 0.001 |
Total proteins (g/L) | -0.306 | 0.032 |
Albumins (g/L) | -0.182 | 0.210 |
Triglycerides (mmol/L) | 0.057 | 0.698 |
Total cholesterol (mmol/L) | -0.114 | 0.439 |
HDL (mmol/L) | -0.153 | 0.298 |
LDL (mmol/L) | -0.1033 | 0.487 |
Urea (mmol/L) | 0.013 | 0.928 |
Creatinine (μmol/L) | 0.133 | 0.356 |
Age (yr) | -0.072 | 0.614 |
Body mass index (kg/m2) | -0.037 | 0.800 |
SBP (mmHg) | 0.387 | 0.005 |
DBP (mmHg) | 0.352 | 0.012 |
IBD duration (yr)2 | 0.0453 | 0.751 |
FC (μg/g) | 0.0483 | 0.812 |
UCEIS (score) | 0.4253 | 0.048 |
SES-CD (score) | 0.4663 | 0.028 |
Table 4 Multiple linear regression model of independent predictors for serum urotensin II levels
Variable | Β1 | SE | t value | P value |
Age | 0.009 | 0.015 | 0.570 | 0.571 |
Gender | -0.740 | 0.405 | -1.825 | 0.075 |
BMI | -0.106 | 0.059 | -1.793 | 0.080 |
SBP | 0.040 | 0.017 | 2.243 | 0.030 |
DBP | 0.039 | 0.025 | 1.535 | 0.132 |
hsCRP | 0.262 | 0.076 | 3.469 | < 0.001 |
- Citation: Alicic D, Martinovic D, Rusic D, Zivkovic PM, Tadin Hadjina I, Vilovic M, Kumric M, Tokic D, Supe-Domic D, Lupi-Ferandin S, Bozic J. Urotensin II levels in patients with inflammatory bowel disease. World J Gastroenterol 2021; 27(36): 6142-6153
- URL: https://www.wjgnet.com/1007-9327/full/v27/i36/6142.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i36.6142